Literature DB >> 137265

Bidirectional amplification of macrophage-lymphocyte interactions: enhanced lymphocyte activation factor production by activated adherent mouse peritoneal cells.

M S Meltzer, J J Oppenheim.   

Abstract

Adherent peritoneal cells (90 to 95% macrophages) from mice injected with Mycobacterium bovis, strain BCG, or certain noninfectious agents such as pyran copolymer or phytohemagglutinin showed increased chemotactic and tumoricidal capacity in vitro. These activated macrophages elaborated 2 to 5 times more lymphocyte-activating factor (LAF) in vitro than equal numbers of adherent cells from untreated mice. In contrast, adherent PC from mice treated with thioglycollate or mineral oil were not cytotoxic and did not produce more LAF than PC from untreated mice. Adherent PC from untreated nude mice, which have increased chemotactic and tumoricidal capacity in vitro, also exhibited enhanced LAF production compared to adherent PC from their normal littermates. Increased production of LAF was also evident with adherent PC and the macrophage-like tumor cell line P388D1 after incubation in vitro with bacterial endotoxins or with antigen-induced lymphokines. These data indicate that adherent PC can be activated either in vivo or in vitro to elaborate more LAF. Thus, activated macrophages are more effective than normal macrophages in amplification of the afferent limb of immune responses as well as in their effector functions.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 137265

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

1.  Effects of L2C leukemia on macrophage-mediated responses.

Authors:  D P Collins
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

2.  Modulation of interleukin 2 receptor expression on normal human lymphocytes by thymic hormones.

Authors:  M B Sztein; S A Serrate; A L Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

3.  Monocyte function in intravenous drug abusers with lymphadenopathy syndrome and in patients with acquired immunodeficiency syndrome: selective impairment of chemotaxis.

Authors:  G Poli; B Bottazzi; R Acero; L Bersani; V Rossi; M Introna; A Lazzarin; M Galli; A Mantovani
Journal:  Clin Exp Immunol       Date:  1985-10       Impact factor: 4.330

4.  Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity.

Authors:  P P Nawroth; D A Handley; C T Esmon; D M Stern
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

5.  Defective interleukin-1 production in a familial monocyte disorder with a combined abnormality of mobility and phagocytosis-killing.

Authors:  A Komiyama; M Ichikawa; H Kanda; K Aoyama; K Yasui; M Yamazaki; H Kawai; Y Miyagawa; T Akabane
Journal:  Clin Exp Immunol       Date:  1988-09       Impact factor: 4.330

6.  Antigen-reactivity pattern of T-cell hybridomas from Mycobacterium bovis BCG-infected mice.

Authors:  I Müller; S H Kaufmann
Journal:  Infect Immun       Date:  1985-09       Impact factor: 3.441

7.  Influence of malaria infection on the elaboration of soluble mediators by adherent mononuclear cells.

Authors:  D J Wyler; J J Oppenheim; L C Koontz
Journal:  Infect Immun       Date:  1979-04       Impact factor: 3.441

8.  Enhanced hydrogen peroxide release from macrophages stimulated with streptococcal preparation OK-432.

Authors:  H Saito; H Tomioka
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

9.  Immunodeficiency with defective T-cell response to interleukin 1.

Authors:  E T Chu; L J Rosenwasser; C A Dinarello; F S Rosen; R S Geha
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

10.  Novel neutrophil chemotactic factor derived from human peripheral blood mononuclear leucocytes.

Authors:  E Kownatzki; A Kapp; S Uhrich
Journal:  Clin Exp Immunol       Date:  1986-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.